Novartis gains approval for Gilenya as a first-line disease modifying oral therapy for multiple sclerosis in Switzerland and Australia

26-Jan-2011 - Switzerland

Swissmedic, the Swiss Agency for Therapeutic Products, and the Australian Therapeutic Goods Administration (TGA) have granted approval for Gilenya® (fingolimod) 0.5 mg as a first-line, oral disease-modifying therapy (DMT) for the treatment of relapsing-remitting multiple sclerosis (RRMS).

"Gilenya, with its innovative mechanism of action, can improve clinical outcomes in patients with relapsing remitting MS," said Professor Ludwig Kappos, Neurology and Department of Research, University Hospital, Basel, Switzerland. "The significant efficacy and manageable safety profile of Gilenya make it a valuable new option for patients with relapsing-remitting MS and the physicians who treat them."

Other news from the department research and development

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance